Member login

Forgot Password?

By using the members area you have already agreed to share your personal information with the BGMA/BBA so that you can access the members materials. We will store your details only as long as you are a member. Your personal information will not be shared any affiliated companies or third parties. For more information about our Privacy Policy, click here.

Return to login
Back to News index

Trade agreement claims

Responding to claims that the NHS would be part of any free trade agreement with the US, Warwick Smith, Director General of the British Generic Manufacturers Association and the British Biosimilars Association, said: “In line with its usual practice in free trade agreements, the US is trying to agree intellectual property requirements which go beyond World Trade Organisation standards and would delay competition from generic and biosimilar medicines that saves the NHS over £13bn per year.

If the US were to be successful, the delay on one blockbuster product could cost the NHS as much as £400m per year. No British Government should put the NHS and its patients at risk in this way.”